Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by BDF Gestion

BDF Gestion raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 118.8% during the third quarter, HoldingsChannel.com reports. The fund owned 3,335 shares of the biopharmaceutical company’s stock after acquiring an additional 1,811 shares during the quarter. BDF Gestion’s holdings in Regeneron Pharmaceuticals were worth $2,529,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $5,682,636,000. Legal & General Group Plc bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $473,872,000. Bank of New York Mellon Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $472,950,000. Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $323,249,000. Finally, Man Group plc bought a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $272,460,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Tuesday, July 7th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Leerink Partners increased their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday, August 17th. Finally, UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the company from $660.00 to $978.00 in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $845.59.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $4.18 during mid-day trading on Monday, reaching $786.56. 167,497 shares of the company were exchanged, compared to its average volume of 818,217. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $80.98 billion, a PE ratio of 19.43, a PEG ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.75 and a 12 month high of $859.34. The company has a fifty day moving average of $791.72 and a 200 day moving average of $721.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm posted $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.